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Dendritic cells (DCs) are the only antigen-presenting cells able to prime naïve T cells and 
cross-prime antigen-specific CD8+ T  cells. Their functionality is a requirement for the 
induction and maintenance of long-lasting cancer immunity. Albeit intensively investigated, 
the in vivo mechanisms underlying efficient antigen cross-processing and presentation 
are not fully understood. Several pieces of evidence indicate that antigen transfer to DCs 
mediated by microvesicles (MVs) enhances antigen immunogenicity. This mechanism 
is also relevant for cross-presentation of those tumor-associated glycoproteins such as 
MUC1 that are blocked in HLA class II compartment when internalized by DCs as soluble 
molecules. Here, we present pieces of evidence that the internalization of tumor-derived 
MVs modulates antigen-processing machinery of DCs. Employing MVs derived from 
ovarian cancer ascites fluid and established tumor cell lines, we show that MV uptake 
modifies DC phagosomal microenvironment, triggering reactive oxygen species (ROS) 
accumulation and early alkalinization. Indeed, tumor MVs carry radical species and the 
MV uptake by DCs counteracts the chemically mediated acidification of the phagosomal 
compartment. Further pieces of evidence suggest that efficacious antigen cross-priming 
of the MUC1 antigen carried by the tumor MVs results from the early signaling induced by 
MV internalization and the function of the antigen-processing machinery of DCs. These 
results strongly support the hypothesis that tumor-derived MVs impact antigen immu-
nogenicity by tuning the antigen-processing machinery of DCs, besides being carrier of 
tumor antigens. Furthermore, these findings have important implications for the exploita-
tion of MVs as antigenic cell-free immunogen for DC-based therapeutic strategies.
Keywords: microvesicles, dendritic cells, antigen-processing, phagosome, radical oxigen species, immune response 
to cancer, tumor antigens, cancer vaccines
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inTrODUcTiOn
Dendritic cells (DCs) are key regulators of the immune response 
and are required to induce long-lasting T-cell-mediated cancer 
immunity (1). Among antigen-presenting cells (APCs), DCs 
own a unique antigen-presenting machinery that endows them 
to cross-process and present exogenous antigens, resulting finally 
in the activation of both CD4+ and CD8+ T cell response (2).
The biological mechanisms underlying the antigen cross-
processing pathways are extensively investigated, also for the full 
exploitation of DCs for immunotherapeutic intervention (3). 
Upon internalization by DCs, exogenous antigens are delivered 
into a complex network of intracellular organelles dynamically 
interacting among each other. Depending on the type and the 
physiological characteristics of each organel, antigens undergo 
to a slow and multistep degradation process that finally allows 
peptide/HLA class I complex formation. The phagosome of 
DCs appears to play a fundamental role in exogenous antigen 
cross-processing by dampening proteases activity, thus reducing 
protein degradation. In particular, it regulates the export/import 
of degraded antigens to/from cytoplasm redirecting them to 
other intracellular pathways for final association to HLA class I 
and II molecules (4).
In vivo, cells release different type of vesicles, distinct for 
biogenesis, size, lipid composition, and molecular cargo. 
Microvesicles (MVs) are regarded as conveyors of biological 
information, able to impact biological behavior of the recipient 
cells even to distant regions of the body, thus mediating physi-
ological and pathophysiological responses (5, 6). Tumor-derived 
MVs seem to play a contradictory role in the complex cross talk 
among cancer cells, immune system, and tumor microenviron-
ment (7, 8). In fact, they can promote tumor growth and foster 
immunosuppressive mechanisms, resulting in tumor dissemina-
tion (9, 10). On the other hand, tumor-derived MVs have been 
proved to be more immunogenic than the soluble antigens (11) 
and to induce efficacious anti-tumor immune responses in vitro 
and in vivo (12–14), suggesting their possible use as immunogen 
for DC-based vaccines (15).
We have recently shown that antigen transfer to DCs medi-
ated by tumor MVs is crucially relevant for cross-presentation of 
tumor-glycosylated antigens such as MUC1. In fact, MUC1 was 
cross-processed and presented to antigen-specific CD8+ T cells 
only when carried by MVs, while the soluble form of MUC1 was 
retained in the HLA class II compartment and did not activate 
any CD8+ T cell response (16).
These pieces of evidence prompted us to postulate that 
tumor-derived MVs could impact the antigen processing in 
DCs. Using MVs derived from ovarian cancer ascites fluid as 
well as from a MUC1 engineered tumor cell line, we show that 
MV internalization modifies DC phagosomal microenviron-
ment, inducing accumulation of reactive oxygen species (ROS) 
and alkalinization. In addition, we showed that MUC1 cross-
processing and presentation to antigen-specific CD8+ T  cells 
depend upon these events.
Our results strongly support the hypothesis that tumor-derived 
MVs convey to DC molecular signals able to reprogram their 
antigen-processing machinery and not just to transfer antigenic 
repertoire. These findings highlight the potential exploitation of 
MVs as antigenic cell-free immunogen for DC-based vaccines.
MaTerials anD MeThODs
recombinant MUc1 glycoprotein (rMUc1)
The rMUC1 was generated by CHO-K1 cells (ATCC CRL-9618) 
transfected with a MUC1-murine-IgG2a fusion cDNA construct 
containing 16 MUC1 tandem repeats. The secreted MUC1-IgG 
was highly sialylated due to the translational modifications occur-
ring in CHO-K1 cells (17). The rMUC1 glycoprotein was purified 
from cell culture supernatant by anion exchange chromatography 
after cleavage of the Fc portion by enterokinase treatment.
cell lines
The lyphoblastoid DG75 cell line (ATCC CRL-2625; kindly 
provided by Prof. P. Trivedi, “Sapienza” University of Rome) 
was cultured in RPMI 1640 medium (Sigma-Aldrich, USA, 
cat n: R0883) supplemented with penicillin 100  U/mL (Sigma 
Chemical Company, USA), streptomicin 100  µg/mL, 2  mM 
l-glutamine, 1% non-essential amino acid, 1% sodium pyruvate 
(all purchased from Sigma), and 10% heat inactivated fetal bovine 
serum (FBS, Euroclone, Italy, cat n: ECS0180L), 5% CO2 at 37°C. 
MUC1-transfected DG75 lymphoblastoid cells (MUC1-DG75) 
generated in our laboratory were cultured as above in presence of 
neomycin (1 mg/mL, Gibco, USA, cat n: 10131-027) (16). Before 
MV production, MUC1-DG75 cells were analyzed for MUC1 
expression by flow cytometry using the MoAb Ma552 clone 
(Monosan, Netherlands, cat n: MONX10513).
Dcs generation
Peripheral blood mononuclear cells (PBMCs) of healthy donors 
were isolated by Ficoll–Hypaque gradient (Lympholite-H, 
Canada, cat n: CL5020) (Policlinico Umberto I Ethics Committee—
Protocol nr. 4214/2016). CD14+ monocytes were magnetically 
immunoselected (StemCell Technologies Inc., CA, USA, cat n: 
18058) and cultured in RPMI 1640 (Sigma-Aldrich) + 10% FBS 
(Euroclone, Italy, cat n: ECS0180L). 50  ng/mL rhGM-CSF and 
rhIL4 (1,000 U/mL, both from R&D Systems, USA, cat n: 215-
GM and 6507-IL, respectively) were added to the cells in culture 
at days 0 and 2 to obtain immature dendritic cells (iDCs). iDCs 
were collected at day 5 and used for the experiments. For activa-
tion of antigen-specific T cell response assay, iDCs were matured 
with inflammatory cytokine cocktail: hrTNFα (10 ng/mL; R&D 
System, cat n: 210-TA), hrIL1β (10 ng/mL; R&D System, cat n: 
201-LB), hrIL6 (10 ng/mL; R&D System, cat n: 206-IL), and PGE2 
1 µg/mL (Sigma-Aldrich, cat n: P6532).
MV Purification
Microvesicles were purified from 400 mL of ovarian cancer ascites 
fluid (MVsAsc) (obtained from stages III patients after informed 
consent from the Department of Gynaecological, Obstetric and 
Urology—Ethical Committee Protocol nr. 1454/2008) and from 
the MUC1-DG75 and DG75 cell lines as previously described 
(16). Briefly, heparinized ascites fluid was centrifuged three 
times at 4°C and ultracentrifuged twice (10,000  ×  g/30  min; 
100,000 × g/1 h; 4°C). To produce MVs from the MUC1-DG75 
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cell line (MVsMUC1-DG75) and the untrasfected DG75 cell line 
(MVsDG75), cells were cultured (3.5  ×  105 cells/mL) in RPMI 
1640 + 2% FBS for 48 h and MVs purified by ultracentrifugation 
steps starting from 300 mL of secretome for each purification. The 
culture medium employed for the production of MVs derived 
from DG75 cell lines (RPMI 1640 + 2% FBS) was processed as 
before described: the final pellet obtained was used as control 
of the MVs present in the 2% FBS. Protein concentration was 
measured by Bradford assay (Bio-Rad Laboratories, USA, cat 
n: 5000006) with an average of 5.5  µg/µL (MVsAsc), 0.9  µg/µL 
(MVsMUC1-DG75), and 1.4 µg/µL (MVsDG75).
nanoparticles Tracking analysis  
(nTa) for MVs
Size determination of MVsAsc and MVsMUC1-DG75 was performed 
by NTA technology (18). MVs were thawed on ice and diluted in 
PBS between 1:500 and 1:20,000 to achieve the optimal number of 
MVs/mL. Three videos (30 s each) were recorded for each sample 
loading, employing the NanoSight NS300 instrument (Malvern 
Instruments Ltd, Malvern, UK). Measurements were performed 
employing the NTA 2.3 analytical software. Results were shown 
as the average of the three recordings.
liposomes Preparation
Zwitterionic lipid 1,2-diarachidoyl-sn-glycero-3-phosphocholine 
(20:0 PC) was purchased from Avanti Polar Lipids (USA cat n: 
850368P). Cholesterol (Chol) was purchased from Sigma-Aldrich 
(cat n: C8667). All lipids were used without further refinement. 
The liposomal formulation was prepared at desired molar ratio 
(Chol:PC =  2:8). Lipids were dissolved in chloroform and the 
solvent was evaporated under vacuum for at least 24  h. Lipid 
film was hydrated with ultrapure water to obtain a final lipid 
concentration of 10 mg/mL and then extruded 20 times through 
a 0.1 µm polycarbonate filter by using the Avanti Mini-Extruder 
(Avanti Polar Lipids).
liposomes size characterization
Liposome size was analyzed employing the Zetasizer Nano ZS90 
spectrometer (Malvern Instruments Ltd.). To this end, liposomes 
were diluted 1:100 with distilled water. The same protocol was 
followed to explore the presence of nano-sized vesicles in the 
ultracentrifuged culture media.
Western Blot
MVsAsc, MVsMUC1-DG75, Liposomes (30 μg/sample), and rMUC1 
(1 µg) were separated on 4–12% SDS-PAGE and blotted onto 
nitrocellulose transfer membrane (Schleicher und Schuell, 
DE, cat n: ST11306-41BL). Prestained protein ladder by 
Nippon Genetics Europe GmbH (cat n: MWPO2) was used. 
Membranes were incubated with anti-MUC1 MoAb Ma552 
(Monosan; 1:100, 1  h at room temperature, RT), followed by 
anti-mouse Fc peroxidase-conjugated antibody [(1:20,000; 
Jackson ImmunoResearch, USA, cat n: 115-036-062); 1  h at 
RT]. Protein bands were detected with enhanced chemilumi-
nescence reagents (ECL Western Blotting Detection, Amersham 
Biosciences, UK, cat n: RPN2106).
Dc Phagosomal ph
Phagosomal pH of monocyte-derived DCs was measured modi-
fying Ref. (19). Briefly, DCs were pulsed in CO2-independent 
medium (Gibco-Life Technologies, UK, #18045-054) with 3 µm 
microbeads (Polysciences Inc., USA, cat n: 17145-5) coupled 
with FITC (pH sensitive, Sigma-Aldrich, cat n: F4274) and 
FluoProbes 647 (pH insensitive, Interchim, France, cat n: 
FP-BZ8810) (106 cells/100 μL; 30 min, 37°C). After washing to 
remove beads, cells were incubated at 37°C (“chased”) for the 
indicated periods of time (10, 20, 30, 60, and 120 min) and imme-
diately analyzed by flow cytometry (FACSCanto II, FACSDiva 
software, BD Biosciences). A FL1(FITC)/FL4(FluoProbes 
647) gate selective for cells that had phagocytosed 1 latex bead 
was employed. Values were compared with a standard curve 
obtained by resuspending DCs that had phagocytosed beads in 
CO2-independent medium at a fixed pH (ranging from pH 5.5 
to pH 8) containing 0.1% Triton X-100 (Bio-Rad Laboratories, 
Inc., Italy, cat n: 1610407). Before pulsing with FITC/FP674 
coupled microbeads, DCs were pulsed (30  min, 37°C) with: 
rMUC1 glycoprotein (20  µg/mL), MVs purified from ovar-
ian ascites fluid or from MUC1-DG75 cells line (500  µg/mL), 
or with Liposomes (2.5  mg/mL). To block NADPH oxidase 2 
(NOX2) activity, 10  µM Diphenyleneiodonium chloride (DPI, 
Sigma-Aldrich, cat n: D2926) was added to DCs 30 min before 
MVs pulsing and it was maintained throughout the experiment.
rOs Detection in Dc Phagosome  
and in MVs
Phagosomal ROS of DCs following MV uptake was meas-
ured modifying the protocol by Savina et  al. (19). Cells were 
pulsed with 3  µm microbeads (Polysciences Inc.) coupled 
with Dihydrorhodamine 123 (DHR123; ROS sensitive, Life 
Technologies, cat n: D-632) and FluoProbes 647 (ROS insensi-
tive, Interchim) (106 cells/100  μL, 15  min, 37°C), in CO2-
independent medium (Gibco-Life Technologies). After pulsing 
with DHR123/FP647 coupled microbeads, DCs were pulsed 
with MVs purified from ascites fluid or from MUC1-DG75 cells 
line (500 µg/mL), with rMUC1 glycoprotein (20 µg/mL) or with 
Liposomes (2.5  mg/mL) (15  min, 37°C). After washing, cells 
were incubated at 37°C (“chased”) for the indicated periods of 
time (0, 10, 20, 30, and 60  min) and immediately analyzed by 
flow cytometry (FACSCanto II, BD Biosciences), using a FL1 
(DHR123)/FL4(FluoProbes 647) gate selective for cells that had 
phagocytosed 1 latex bead. To enhance or block phagosomal ROS 
production, phorbol 12-myristate 13-acetate (PMA, 0.5 µg/mL, 
Sigma-Aldrich, cat n: P8139) and DPI (5  µM, Sigma-Aldrich), 
respectively, were added to DCs 30 min before pulsing and were 
kept throughout the experiment. ROS values were obtained by 
comparing the DHR123/FP647 ratio of pulsed and unpulsed 
DCs  ±  DPI/PMA at different time of chase (10, 20, 30, and 
60 min) with the unpulsed DCs at time 0 of chase.
Radical content in MVs was determined by 2′,7′-dichlorofluorescin 
diacetate (DCF-DA, Sigma-Aldrich, cat n: D6883) staining. 
MVs from ascites fluid and MUC1-DG75 were incubated in 
PBS + 10 mM DCF-DA (40 min, 37°C in the dark). After washing 
with PBS, samples were analyzed by flow cytometry (FACSCanto II, 
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BD Biosciences). Fluorescent Nile Red particles (Spherotech, 
US, cat n: FP-0256-2) with size of 100–300 nm were used as size 
marker. Protein-empty Liposomes were used as negative control. 
To test the overall presence of ROS generating molecules 10 mM 
H2O2 was added (Sigma-Aldrich, cat n: H1009).
immunofluorescence Microscopy
After pulsing with MVsAsc, DCs ± DPI were cytospun (8 × 104 
cells/sample) and fixed with cold acetone/methanol (1:1; VWR 
Chemicals, France, cat n: 2006-321 and 200659-6, respectively). 
After blocking with 20% Bovine Serum Albumine (Sigma-Aldrich, 
cat n: A2153), DCs were incubated (45 min) with the anti-MUC1 
MoAb Ma552 (1:20) followed by Alexa 488-conjugated goat anti-
mouse F(ab′)2 (1:100, 30 min; Jackson ImmunoResearch, cat n: 
115-546-008). After blocking and washing, the samples were 
incubated with PE/Texas red-conjugated HLA-II-DR (30 min in 
the dark, Beckman Coulter, cat n: IM3636) to detect the HLA 
class II compartment. To visualize HLA class I compartment, 
the following reagents were employed: the rabbit polyclonal 
antibody anti-calreticulin (1:50, 45  min; Stressgen, US, cat n: 
SPA-600) followed by Texas red-conjugated goat anti-rabbit 
antibody (1:200, 30 min in the dark; Jackson ImmunoResearch, 
cat n: 111-075-144) and anti-HLAI MoAb W6/32 (culture super-
natant) followed by Cyanine Cy™3 affiniPure F(ab′)2 fragment 
goat anti-mouse IgG (Jackson ImmunoResearch, cat n: 715-166-
150, 1:1500). Calreticulin/EEA1 intracellular distribution was 
evaluated employing: anti-calreticulin polyclonal antibody and 
anti-EEA1 MoAb (BD Transduction Laboratories, cat n. 610456, 
1:50) revealed by FITC-conjugated goat anti-rabbit IgG (Jackson 
ImmunoResearch, cat n: 111-096-144, 1:200) and Cyanine Cy™3 
affiniPure F(ab′)2 fragment goat anti-mouse IgG (Jackson Immuno 
Research), respectively. Unpulsed DCs were used as negative con-
trol. All incubations were carried out at RT. Fluorescence signals 
were visualized with an Axiovert 200 inverted microscope (Zeiss, 
Germany); cells were scanned in a series of 0.5  µm sequential 
sections with an ApoTome System (Zeiss) and images were all 
acquired by the digital camera Axio CAM MRm (Zeiss). Image 
analysis was performed by the Axiovision software (Zeiss) and 
reconstruction of a selection of three central optical sections 
was shown in each figure. Quantitative analysis of the extent of 
colocalization of fluorescence signals was performed using the 
KS300 3.0 Image Processing System (Zeiss). The mean ± SD per-
cent of colocalization was calculated analyzing a minimum of 30 
cells for each treatment randomly taken from three independent 
experiments.
MUc1+ cD8+ T cell enrichment  
and iFnγ-elispot
MUC1-enriched CD8+ T  cells were expanded in culture 
from PBMCs of a MUC1 vaccinated ovarian cancer patient 
(open-label phase I/II safety clinical peptide vaccination 
trial, approved by Policlinico Umberto I Ethics Committee 
and Italian National Institute of Health/protocol no. LITRM/
DIMIGE05/01; Ethical Committee Protocol nr. 1454/2008) 
(20). Briefly, PBMCs were isolated by Ficoll/Hypaque density 
gradient and CD8+ cells were immunoselected (Stemcell 
Technologies, USA, cat n: 18053) and kept in RPMI  +  5% 
FCS. CD8− cells (2  ×  106 cell/mL) were pulsed overnight 
(o/n) with 50  µg/mL of MUC1159-167 peptide (SAPDNRPAL) 
(ClinAlfa, Switzerland, C-S-270/ACO598) and 5  µg/mL 
β2-microglobulin (Sigma Aldrich, cat n: 4890) in RPMI, 1% FCS. 
CD8− cells were then irradiated (30 Gy) and plated with autolo-
gous CD8+ T cells (1:1; 2 ×  106 total cells/mL) in RPMI +  5% 
FCS, supplemented with IL2 (50 UI/mL; Prepotech, USA, cat n: 
200-02) and IL7 (10 ng/mL; R&D System, cat n: 207-IL). After 
7  days, freshly isolated and MUC1-pulsed autologous PBMCs 
were irradiated and added to the culture (1:1). At the same 
time, autologous CD14+ cells were isolated and differentiated 
into iDCs as above described. At day 5, iDCs were harvested: 
half of the iDCs were incubated with 10 nM DPI for 30 min in 
RPMI 1640 for DC culture (2 × 106/mL). iDCs were then pulsed 
o/n with MVs from the DG75 cells (400  µg/mL), MVs from 
MUC1-DG75 cells (400  µg/mL) and MUC1159-167 peptide with 
β2-microglobulin (50 and 5 µg/mL, respectively), in the presence 
or absence of 10  nM DPI. After 4  h, iDCS were matured with 
the cytokine cocktail o/n. mDCs were then washed and added 
to MUC1+ enriched CD8+ T  cells (1:5), previously expanded 
in culture and purified by Ficoll/Hypaque density gradient to 
remove cell debris. DCs/T cells were plated (2 × 106cell/mL) in 
duplicate o/n in the anti-IFNγ-precoated (1:200; BD Biosciences, 
cat n: 51-2555KZ) ELISpot plate (MultiScreen, Merck, Germany, 
cat n: S2EM004M99). Unpulsed DCs +  T  cells samples were 
used as negative control. IFNγ cytokine release was detected with 
biotinylated anti-IFNγ antibody (1:250, 2 h; BD Bioesciences, cat 
n: 51-1890KZ), revealed with streptavidin-alkaline phosphatase 
(BD Biosciences 554065) (1:1,000, 100 mL/well, 1 h) and chro-
mogen substrate (Sigma, B5655). Spots were counted using the 
ImmunoSpot Image Analyzer (Aelvis, Germany). Average value 
of background control samples (unpulsed DCs +  T  cells) was 
subtracted from average value of each experimental condition. 
IFNγ response was considered positive adopting as cutoff a two-
fold increase (IFNγ production induced by DCs + MVsMUC1-DG75/
IFNγ production induced by DCs + MVsDG75).
elisa
Flat-bottomed 96-well EIA/RIA plates (Costar, USA, cat n: 
3690) were coated with 2 µg/well of MVAsc and MVsMUC1-DG75 in 
Carbonate Buffer o/n. Plates were washed and incubated with 
PBS-5%BSA (Sigma-Aldrich, cat n: A4503). After three washes 
in PBS-1%BSA-0.01% Tween 20 (Biorad, cat n:1706531), samples 
were incubated for 1 h, 37°C with relevant antibody, in duplicates. 
The following MoAbs were used at 2  µg/mL, when otherwise 
specified: anti-CD9 (Abcam, England, ab58989), anti-GM130 
(SantaCruz Biotechnologies, USA, cat n: sc-55591), MOPC21 
(Sigma-Aldrich, M-7894), MoAb Ma552 clone (Monosan, 1:100).
The polyclonal rabbit Abs used were: anti-CD63 (SantaCruz 
Biotechnologies, cat n: sc-15363, 1:200), anti-TGN46 (Sigma, 
USA, cat n: T7576, 1:1,500); Normal Rabbit Serum (NRS) 
(ThermoFisher Scientific, USA, cat n: 10510; 1:1,000). 
Peroxidase-conjugated affinity purified F(ab′)2 goat anti-mouse 
IgG (H + L; 1:5,000, Jackson ImmunoResearch cat n: 115-036-
062) or affinity purified F(ab′)2 goat anti-rabbit (H + L; 1:5,000, 
Jackson ImmunoResearch cat n: 111-036-045) was added to wells 
(1 h RT), washed and followed by chromogen addiction (5 mg 
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O-phenylenediamine, Sigma, cat n: P6912) in citrate phosphate 
buffer 10 mL and 30% H2O2 10 µL (Sigma-Aldrich). The absorb-
ance was measured at 492 nm. Sample ODs were subtracted of 
the OD values of control samples (MOPC1 and NRS OD value 
for MoAb and rabbit antibodies, respectively).
statistical analysis
Statistics was performed using GraphPad Prism software, version 
6 (GraphPad Software, Inc., USA). Results were expressed as mean 
values ± SD. p values were calculated using Student’s t-test when 
comparing two groups of continuous variables. Significance level 
was defined as p-value <0.05 (*p < 0.05; **p < 0.01; ***p < 0.005).
resUlTs
MV Uptake induces alkalinization  
in Dc Phagosomal compartment
In DCs, alkalinization of the phagosomal compartment seems to 
be crucial for efficient antigen cross-processing and presentation 
(4). We have previously shown that the tumor-associated MUC1 
is cross-processed by DCs when the glycoantigen is carried by 
MVs, not when MUC1 tumor-associated glycoprotein is internal-
ized as soluble molecule (16). We hypothesized that MVs could 
impact phagosome microenvironment, thus signaling to DCs for 
a distinct antigen-processing pathway.
To test this hypothesis, distinct tumor MV formulations were 
employed. Cell-derived extracellular vesicles were purified by 
ultracentrifugation from ovarian cancer ascites fluid and from 
the supernatant of the MUC1-DG75 cell line, a lymphoblastoid 
cell line engineered to express MUC1 also in the MVs (16). Size 
analysis of MV samples was performed by NTA technology. 
Ovarian cancer ascites fluid-derived vesicles (MVsAsc) were 
mostly distributed within the range between 105 and 375  nm, 
with an overall average size of 194.6 nm (Figure 1A). Extracellular 
vesicles from MUC1-DG75 cell line (MVsMUC1-DG75) were also het-
erogeneous for size, as previously characterized by transmission 
electron microscopy (TEM) (16, 21). NTA analysis showed two 
main vesicles subsets having a medium size of 105 and 170 nm, 
respectively (mean size: 130 nm) (Figure 1B).
The MVs were characterized for the presence of intracel-
lular compartment markers. Exosome markers such as CD9 
and CD63 as well as calnexin (ER marker) and GM130 (Golgi 
marker) were expressed at low levels (Figure 1C) in both vesicle 
samples. TGN46, marker for trans-Golgi network compartment, 
was also detected. The MUC1 tumor antigen was present at high 
levels in both vesicle samples as detected by ELISA and WB 
(Figures 1C,E).
These results suggest that extracellular vesicles obtained were 
heterogenous for size and intracellular origin, with a prevalence 
of vesicles derived from the plasma membrane/exocytic pathway 
as indicated by the size (>100 nm) and the presence of MUC1 
and TGN46 markers.
As “protein free vesicles,” Liposomes were produced with a 
medium size of 160  nm, corresponding to the average size of 
the tumor-derived MVs (Figure 1D). Liposomes were made by 
Zwitterionic lipid 1,2-diarachidoyl-sn-glycero-3-phosphocholine 
andChol to resemble the lipid pattern of plasma membrane. Also 
the rMUC1 carrying tumor-associated glycans (22) was employed 
as soluble MUC1 form (Figure 1E).
Dendritic cells were pulsed with MVsAsc, MVsMUC1-DG75, 
Liposomes, and rMUC1, and phagosomal pH was monitored for 
2 h by flow cytometry (Figure 2). Unpulsed DCs, employed as 
control, showed a neutral phagosomal pH (7.01–7.03 pH) for the 
first 20 min of chase that increased up to 7.32 ± 0.081 SD pH at 
60 min. When DCs were pulsed with MVsAsc (DCs + MVsAsc), 
phagosomal pH significantly increased compared to unpulsed 
DCs already at 20 min, reaching 7.34 ± 0.108 SD pH (p < 0.05) 
after 30  min of chase. After 1  h, pH reached similar values in 
both DCs and DCs +  MVsAsc (Figure  2A). Similar pH kinetic 
was observed when DCs were pulsed with MVsMUC1-DG75: again 
a significant increase of phagosomal pH was observed within 
the first 30  min of chase (7.39 ±  0.05 SD pH, p <  0.05) and 
similar pH values for both samples were reached after 1  h of 
chase (Figure 2B). To exclude that this effect was due to vesicle 
contaminant in the bovine serum, DCs were incubated with the 
pellet fraction obtained by the ultracentrifugation of the culture 
medium (RPMI + 2% FBS) and displayed a pH kinetic similar 
to the untreated DCs (Figure S1A in Supplementary Material). 
Results of size analysis of this pellet were not compatible with 
the presence of vesicles, but they corresponded to a typical size 
distribution of proteins enriching culture media (23) (Figure S1B 
in Supplementary Material).
Uptake of soluble rMUC1 glycoprotein and the protein free 
Liposomes did not affect phagosomal pH (Figures 2C,D, respec-
tively), suggesting that the rapid DC phagosomal alkalinization 
observed is a specific response to uptake of the tumor-derived 
MVs.
MV internalization by Dcs induces 
increase of rOs levels in Dc Phagosomal 
compartment
Since phagosomal alkalinization seems to be strictly dependent 
on reactive oxygen species (ROS) generation and consequently 
protons consuming (24), the level of ROS into the DC phagosomal 
compartment was measured following MVsAsc internalization in 
time course experiments (Figure 3A, dotted lines). Phagosomal 
radical species were consistently higher in MVsAsc pulsed DCs 
than in unpulsed DCs, being statistically significant in the first 
30 min of chase.
It appeared that ROS increase occurred shortly before the 
pH alkalinization (Figure 3A, continuous lines), if considering 
the MVsAsc pulsing of DCs as T0 for both phagosomal ROS and 
pH measurement. Similar results were obtained when DCs were 
pulsed with MVsMUC1-DG75 (data not shown). This might suggest 
that MVs of tumor origin trigger phagosomal ROS production 
and pH increase as consequence.
Reactive oxygen species modulation in DCs was then analyzed 
at 30 min of chase after pulsing with tumor-derived MVs (MVsAsc 
and MVsMUC1-DG75; Figure 3B) and with both Liposomes and the 
soluble rMUC1 (Figure 3C).
When both MVsAsc and MVsMUC1-DG75 were used to pulse DCs, 
ROS significantly increased (p < 0.05) as compared to unpulsed 
FigUre 1 | Characterization of tumor-derived microvesicles (MVs) and Liposomes. (a,B) Size measurement of MVs derived from ovarian cancer ascites 
fluid [MVsAsc; (a)] and shed by the MUC1-transfected DG75 lymphoblastoid cell line [MVsMUC1-DG75; (B)] using Nanosight NS300 that employs nanoparticles 
tracking analysis (NTA) technology. Results are plotted as graph; y-axis: concentration of particles; x-axis: size of particles in nanometer. The black curve is 
obtained by the merge of three independent measurements for each MV sample. SD and the medium sizes of identified vesicle subsets are shown above 
the merged curve. Legend shows the particle medium size of the entire sample and the dimension of the 10, 50, and 90% of vesicles in the sample (D10, 
D50, and D90, respectively). (c) CD9, CD63, Calnexin, GM130, TGN46, and MUC1 proteins expression in MVsAsc (white histograms) and MVsMUC1-DG75 
(black histograms) as detected by ELISA assay (O.D. 492). Sample ODs were subtracted of the OD values of control samples [MOPC1 and Normal Rabbit 
Serum (NRS)]. Results are plotted as average and SD of two independent experiments. (D) Liposomes size measurement using Zetasizer Nano ZS90 that 
employs NTA technology. Results are plotted as graph; y-axis: mean intensity percentage; x-axis: size of particles. The black curve shows the 
representative Liposomes dimension out of five different size measurements. (e) MUC1 expression in vesicle samples. MUC1 was detected by Western 
Blot analysis employing the MoAb Ma552. MVsAsc and MVsMUC1-DG75 were positive, while Liposomes were negative. The recombinant MUC1 glycoprotein 
(rMUC1) was used as positive control.
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DCs, although at a lower extent than DCs treated with PMA, used 
as stimulus to maximize ROS production (p < 0.01) (Figure 3B). 
No change in radical species was observed when Liposomes or 
soluble rMUC1 glycoprotein were employed (Figure 3C). These 
results indicate that only tumor-derived MVs could modulate 
ROS accumulation into the phagosomal compartment of DCs, 
probably inducing the DC phagosomal alkalinization.
Tumor MVs carry rOs species and 
contribute to Phagosomal alkalinization
These results prompted us to investigate whether tumor-derived 
MVs carried endogenous source of radical species. Liposomes, 
MVsAsc and MVsMUC1-DG75 were first identified by SSC-FSC 
analysis in flow cytometry and gated employing 100–300  nm 
beads as reference (Figure S2 in Supplementary Material). These 
FigUre 2 | Increase of dendritic cell (DC) phagosomal pH following internalization of tumor-derived MVs. Time course experiments to evaluate the phagosomal pH 
values in unpulsed DCs (gray line) and DCs pulsed with MVsAsc (a), MVsMUC1-DG75 (B), recombinant MUC1 glycoprotein (rMUC1) (c), and Liposomes (D) (black line). 
Each graph shows the average and SD of independent experiments. DC phagosomal pH significantly increased (*p < 0.05) when DCs were pulsed with MVs 
purified from ovarian cancer ascites fluid [(a), five independent experiments] or shed by DG75 cell line [(B), three independent experiments] (*p < 0.05 at 20 and 
30 min). No change in phagosomal pH was observed when rMUC1 glycoprotein [(c), 5 independent experiments] or Liposomes  
[(D), four independent experiments] were used to pulse DCs.
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measurements were in agreement with the MV size distribution 
as determined by NTA analysis (Figure 1).
The radical species content of Liposomes, MVsAsc and 
MVsMUC1-DG75 was measured by staining with the ROS sensitive 
dye DCF-DA. Results indicated that while Liposomes remained 
negative, MVsAsc and MVsMUC1-DG75 were positive for DCF-DA 
staining while (Figure  4A, a–c, respectively). The exogenous 
addition of H2O2 induced appearance of staining in Liposomes 
sample (13.02-fold MFI increase, Figure  4A, d) and a slight 
increase of reactivity in MVsAsc and MVsMUC1-DG75 (1.25- and 
2.82-fold MFI increase, respectively, Figure 4A,e,f, respectively).
To assess whether radical species carried by tumor MVs 
functionally impacted DC phagosomal activity, DCs were 
treated with DPI, specific inhibitor of NOX2, a key enzyme in the 
fine tuning of ROS production in DCs (25). As expected, ROS 
level significantly decreased (p <  0.01) in DPI-treated DCs as 
compared to untreated DCs (Figure 4B). Addition of MVsAsc to 
DPI-treated DCs significantly restored radical species (p < 0.05) 
at similar levels to untreated DCs (Figure  4B). When pH was 
measured in time chase experiments, DPI treatment induced 
phagosomal acidification (p < 0.01) throughout the experiment 
(10–120  min) (Figure  4C). Pulsing of DPI-treated DCs with 
MVsAsc significantly increased the pH values in the first 60 min 
(p < 0.05), restoring alkalinization in the phagosome at pH values 
close to untreated DCs (Figure 4C). Similar results were obtained 
when DCs were pulsed with MVsMUC1-DG75, while no change was 
observed when Liposomes were employed (data not shown). 
These results indicate that the phagosomal alkalinization upon 
MVs’ internalization is dependent upon ROS increase.
Dc Phagosomal alkalinization induced by 
Tumor MVs enhances MUc1 Processing 
to hlai compartment and cross-
Presentation of MUc1 antigen requires 
Functional Dcs
In order to clarify the physiological role of phagosomal alkaliniza-
tion induced by tumor MVs in MUC1 antigen cross-processing, 
the intracellular re-localization of MUC1 was analyzed by immu-
nofluorescence in DCs pulsed with MVsAsc, treated or not with DPI.
After 12  h pulsing, MUC1 detection was strongly reduced 
in DCs treated with DPI (p < 0.005) as compared to untreated 
DCs, suggesting that the forced acidification induced by DPI had 
impacted degradation of the MUC1 (Figure S3A in Supplementary 
Material).
In DPI-untreated DCs, MUC1 mostly colocalized with calreti-
culin (53%), ER protein employed as HLA class I pathway marker 
(Figure 5A, a–c). The MUC1 antigen was scarcely associated with 
HLA-II compartment marker HLA-II-DR (<10%) (Figure 5A, d–f).
Diphenyleneiodonium chloride treatment also affected 
MUC1 intracellular distribution: MUC1/HLAII-DR colocaliza-
tion significantly increased (38%, p < 0.05) and was distributed in 
intracellular dots strongly suggesting that HLA class II pathway 
was engaged (Figure 5A, j–l). Conversely, MUC1 distribution was 
FigUre 3 | Phagosomal reactive oxygen species (ROS) molecules increase following dendritic cell (DC) uptake of tumor microvesicles (MVs) shortly before 
phagosomal alkalinization. (a) Modulation of the phagosomal ROS (dotted lines) and pH (continuous lines) in DCs following internalization of MVsAsc considered as 
T0 for both the kinetic measurements. Results are plotted as average of 4 independent experiments for ROS analysis and 5 independent experiments for 
phagosomal pH analysis. SD and statistical significance are also shown (*p < 0.05). (B) ROS measurement at 30 min of chase; MV pulsed DCs (light and dark gray 
histograms for DCs + MVsAsc and DCs + MVsDG75-MUC1 samples, respectively) had a significant higher ROS content compared to unpulsed DCs (white histogram, 
*p < 0.05). PMA-treated DCs (black histogram) are used as positive control. ROS levels are plotted as arbitrary units of three independent experiments (three 
donors) normalized toward the unpulsed DCs at time 0 of chase (100 arbitrary units). (c) ROS measurement at 30 min of chase; DCs pulsed with Liposomes (light 
gray histogram) and with the soluble recombinant MUC1 glycoprotein (rMUC1) glycoprotein (dark gray histogram) did not show any difference in term of ROS 
content compared to unpulsed DCs (white histogram). PMA-treated DCs (black histogram) were used as positive control. ROS levels are plotted as arbitrary units of 
three independent experiments (three donors). ROS level in unpulsed DCs at time 0 of chase correspond to 100 arbitrary units (dotted line). *p < 0.05; **p < 0.01.
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reduced, although not abolished, in calreticulin compartment 
(25%, p < 0.05) (Figure 5A, g–i). Similar results were obtained 
when the HLA class I molecule was employed as compartment 
marker (Figure S3B in Supplementary Material). No overlap 
between calreticulin+ compartment and early endosome (EEA1+) 
compartment was observed (Figure S3C in Supplementary 
Material). When DCs (±DPI treatment) were pulsed with 
MVsMUC1-DG75, similar MUC1 intracellular distributions in HLA 
class I and class II compartments were observed as compared to 
MVsAsc pulsed DC cells (data not shown).
The impact of reduced MUC1 antigen cross-processing on anti-
gen presentation was analyzed as MUC1-specific T cell responses.
MUC1-specific CD8+ T  cells were expanded from PBMCs 
of an ovarian cancer patient, previously vaccinated with the 
HLAI-A2-restricted MUC1159-167 peptide (20). Autologous DCs 
(±DPI treatment) were pulsed with MVsMUC1-DG75, MVsDG75 (MVs 
from untransfected DG75 cells) or loaded with the immunogenic 
MUC1159-167 peptide. Unpulsed and pulsed DCs were used as 
APCs to stimulate the enriched MUC1159-167 specific CD8+ 
T cells. T cell activation was evaluated as IFNγ release in ELISpot 
assay. As Figure  5B reports, DCs  +  MVsMUC1-DG75 induced a 
stronger IFNγ T-cell mediated response than the one induced 
by DCs  +  MVsDG75, indicating that specific antigen response 
occurred, in agreement with what previously reported (16).
FigUre 4 | Tumor microvesicles (MVs) are source of radical species and modulate phagosomal alkalinization. (a) The presence of reactive oxygen species (ROS) 
molecules in Liposomes (a, d), MVsAsc (b, e), and MVsMUC1-DG75 (c, f) was analyzed used DCF-DA (a–c) and DCF-DA + H2O2 as positive control (d–f). Results are 
plotted as graph; y-axis: event count; x-axis: Log-FITC-A (from 0 to 105). White histograms are referred to the background fluorescence of Liposomes and MVs 
samples, gray histograms represent Liposomes and MVs treated with DCF-DA (a–c) or with DCF-DA + H2O2 (d–f). The mean fluorescence intensity for untreated 
sample, DCF-DA-treated and DCF-DA + H2O2 samples were, respectively: MFI 2, 18, 229 for Liposomes; MFI 5, 381, 481 for MVsAsc; MFI 9, 75, 212 for MVsMUC1-
DG75. (B) ROS species measurement in DPI-treated DCs following MVsAsc pulsing. MVsAsc uptake (black histogram) restored ROS levels in DPI-treated DCs (gray 
histogram) similarly to unpulsed DCs (withe histogram). ROS levels are plotted as arbitrary units of three independent experiments (three donors). ROS level in 
unpulsed DCs at time 0 of chase correspond to 100 arbitrary units. *p < 0.05; **p < 0.01. (c) Phagosomal pH measurement in DCs in the presence of DPI, without 
or with MVsAsc pulsing. Diphenyleneiodonium chloride (DPI) treatment decreased pH compared to untreated DCs (black line, squared vs. black line, dotted). In MVs 
pulsed DPI-treated DCs (gray line, triangle) phagosomal pH was partially restored. The difference between DPI-treated DCs (black line, squared) and MVs pulsed 
DPI-treated DCs (gray line, triangle) is statistically significant from 20 to 60 min of chase (*p < 0.05). Values are mean ± SD of three independent experiments.
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When DCs were pulsed in the presence of DPI, the IFNγ 
response to DCs + MVsMUC1-DG75 drastically dropped (80% reduc-
tion) and was abolished for DCs + MVsDG75 (Figure 5B).
As expected, DCs directly loaded with the immunogenic 
peptide induced equal IFNγ T-cell-mediated production, inde-
pendently by DPI treatment, confirming the specificity of the 
IFNγ response to the MUC1 peptide (Figure 5B).
These results show that the uptake of tumor MVs carrying 
endogenous source of radical species still sustains a mild MUC1 
degradation favoring antigen translocation into the endoplasmic 
reticulum, albeit a fully competent DC is required so that optimal 
cross-presentation may occur.
DiscUssiOn
Release of tumor-derived MVs is emerging as a crucial factor 
in mediating the complex cross talk among transforming cells, 
immune system and local microenvironment during tumor 
progression (7).
In vivo, tumor MVs most probably exert these distinct and 
apparently contradictory roles depending upon the stage of 
tumor transformation: initially, tumor-derived MVs deliver 
antigenic repertoire to DCs present in the tissue and resident in 
the adjacent lymph nodes contributing to immunesurveillance 
(26, 27). Then cell transformation and the immune sculpting 
FigUre 5 | Tumor microvesicles (MVs) induce MUC1 processing to HLAI in dendritic cells (DCs) with acid phagosomal compartment, while cross-presentation of 
MUC1 antigen requires functional DCs. (a) Intracellular localization of MUC1 carried by MVsAsc in DCs (a–f) and in diphenyleneiodonium chloride (DPI)-treated DCs 
(g–l) was visualized by immunofluorescence staining after 12 h of internalization employing the anti-MUC1 MoAb Ma552 (green, a, d, g, j) and antibodies direct 
against specific markers for intracellular compartments (red). In particular: anti-calreticulin rabbit polyclonal antibody for ER (b, c, h, i) and anti-HLAII-DR for HLA-II 
compartment (e, f, k, l). Colocalization of the green and red immunofluorescence signals is shown in yellow (c, f, i, l). Quantitative analysis of colocalization was 
calculated as reported in material and methods and plotted as histograms. Results are expressed as mean values ± SD. Student’s t-test was performed and 
significance level has been defined as p < 0.05. *p < 0.05. Bar: 10 µm. (B) ELISpot assay to evaluate the IFNγ cytokine secretion by MUC1-specific enriched CD8+ 
T cells from an ovarian cancer patient in response to mDCs (white histograms) and mDCs + DPI (black histograms) pulsed with MVsDG75, MVsMUC1-DG75 and 
MUC1(159-167) peptide. Results are shown as average and SD of replicates.
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processes give rise to transformed cell clones with high immune 
suppressive potential and tumor MVs shift their function mediat-
ing immunesuppression (28, 29).
The immunoactivatory role of MVs probably lies in their 
ability to reprogram DC functions, besides simply convey a 
tumor antigenic repertoire to APCs. DCs are activated by tumor 
MVs through delivery of tumor DNA that triggers a protective 
anti-tumor immune response in vivo (30, 31). Also indirect pieces 
of evidence suggest that MV internalization modulates antigen 
cross-processing ability of DCs. In fact, DCs appear more effi-
cient in cross-priming antigens carried by MVs than the soluble 
antigens (11, 32) and only when carried by MVs, large tumor 
glycosylated antigens as MUC1 are cross-presented and CD8+ 
T cell responses are activated (16).
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This biological mechanism may also pertain to other tumor-
associated glycoproteins that compose for a large proportion the 
immunogenic repertoire of tumor cells.
These results prompted us to hypothesize that tumor MVs could 
act as signalosome for DCs, modifying the intracellular routing of 
the antigenic cargo and inducing HLA class I processing.
Dendritic cell phagosome appears to be a key cell compart-
ment balancing the cross-processing of internalized exogenous 
antigens (3). Thus, we investigated the effect of MV internalization 
by DCs on phagosomal compartment, employing tumor-derived 
MVs obtained from ovarian cancer ascites fluid (MVsAsc) and 
from the MUC1-DG75 line (MVsMUC1-DG75).
A single cell simultaneously sheds several subsets of extra-
cellular vesicles generated by distinct biogenesis processes and 
characterized by a specific size range and distinctive molecular 
cargo. Both MV samples contained different vesicle subsets 
heterogeneous for size as detected by NTA analysis. The tumor 
MVs had a mean size of 194 and 130 for MVsAsc and MVsMUC1-DG75, 
respectively. This corresponded to the size of vesicles generated by 
membrane evagination (6). Biochemical characterization further 
suggested that vesicle samples were originated from distinct 
intracellular compartments, with a prevalence of vesicles derived 
from the plasma membrane/exocytic pathway. Both the tumor 
MV samples carried the MUC1 tumor-associated glycoprotein.
Following uptake of MVsAsc by DCs, after 12  h, MUC1 was 
found in association with calreticulin and HLAI molecules, 
markers for HLA class I compartment, indicating that cross-
processing occurred.
In addition, pulsing of DC cells with MUC1-carrying MVs 
induced a T-cell-mediated response evaluated as IFNγ production.
The cross-processing ability is an exquisite feature of DCs 
and it is determined by a finely tuned proteolytic activity: in 
fact, DCs exhibit a reduced capacity for phagosomal degradation 
than do other APCs. It is thought that the partial degradation of 
the internalized antigens occurring in the phagosomes sustains 
antigen stability. This promotes antigen export to the cytosol, 
where further degradation by proteasome occurs, generating the 
peptide repertoire for HLA class I loading (4). The alkalinization 
of phagosome environment regulates protease function and 
is finely tuned by a dynamic and balanced activity of NOX2 
and the V-ATPase proton pump (24). In vivo, DCs with higher 
cross-presenting ability, such CD8α+ DCs, are characterized by 
phagosomes with alkaline microenvironment that is sustained 
by enhanced ROS accumulation (33). Conversely, inhibition of 
ROS production lowers phagosomal pH leading to block of cross-
processing and presentation (34).
Indeed, transfer of the MUC1 antigen to DCs by MVsAsc or 
MVsMUC1-DG75 induced a phagosomal ROS increase and a mild, but 
significant, phagosomal alkalinization in the first 30 min of chase.
The early alkalinization observed was dependent upon the 
ROS accumulation triggered by MV uptake. In fact, in DCs 
treated with the NOX2 inhibitor DPI with a consequent acid 
phagosomal pH, MV internalization restored phagosomal ROS 
and pH levels.
Internalization of the soluble rMUC1 did not induce such 
events as expected since MUC1 processing is confined to HLA 
class II compartment (16, 35). Also Liposomes internalization 
did not trigger ROS and pH increase, suggesting that the changes 
in the phagosomal environment were not a general response to 
vesicle uptake.
It has been shown that phagosomal ROS and pH increase 
occurs when soluble antigen is immobilized on inert material or 
onto polystyrene beads with a size >500 nm (36, 37). This does 
not apply to our system both for the composition and for the size 
of MVs and Liposomes employed (size <500 nm) suggesting that 
the molecular cargo of tumor MVs could be responsible for the 
modification induced at DC phagosomal level.
So far, biochemical and proteomic pieces of evidence indicate 
that radical species as well as redox enzymes can be found in 
diverse vesicle subsets from a variety of cell types (38, 39). The 
cargo radical activity of MVs has shown to be relevant in bio-
logical processes of diverse type of cells and tissues as such as 
endothelial barrier, cardiomyocytes, and epithelial cells (40–42).
Indeed both MVsAsc and MVsMUC1-DG75 were source of radical 
species as tested by staining with DCF-DA, a probe sensitive to 
radicals (43). It is unlikely that the oxidant anions per se could 
make account for the phagosomal ROS increment observed in 
MVs pulsed DCs due to their high instability (i.e., the isolation 
and storage processes could dampen anion reactivity). It is con-
ceivable that MVs might carry enzymes producing radical species. 
This hypothesis would be also in agreement with the kinetics of 
ROS triggering and pH early increase that we observed. Recently, 
it has been shown that NOX2 carried by MVs is functional in 
producing ROS and mediating Treg functions (44). Interestingly, 
preliminary data indicate that NOX2 was present in both MVsAsc 
and MVsMUC1-DG75 (data not shown) and ongoing studies are cur-
rently being carried out to investigate the redox enzyme(s) that 
can be involved in this process.
Nevertheless, MVs molecular repertoire by itself does not 
appear to be sufficient to translate phagosomal alkalynization in 
optimal antigen presentation. Indeed, MVs internalization sig-
nificantly restored ROS and pH levels in DPI-treated DCs (2 h). 
Prolonged DPI treatment of DCs (14 h) drastically decreased, but 
not abolished, MUC1 translocation to ER/HLAI. Concurrently, 
a dampened activation of MUC1 antigen-specific CD8+ T  cell 
response was observed.
These results suggest that while MV internalization could be 
a triggering event, the recipient DCs need to be equipped with 
a competent antigen-processing machinery to activate an effica-
cious antigen presentation.
Preliminary results are indicative that phagosome maturation 
process may be differently modulated by tumor MV uptake, not 
by Liposomes (data not shown).
The phagosome is a central cellular hub for docking and sort-
ing of antigens, fated to degradative/antigen presenting intracel-
lular pathways. The cross talk among these distinct compartments 
is crucial for the antigen presentation machinery, although the 
mechanisms underlying cross-presentation are still unclear (45). 
Several molecules, key regulators in the protein import/export 
from intracellular compartments, seem to play a critical role in 
antigen cross-priming. Recently, Sec22b, a SNARE family member 
modulating the protein trafficking from ER to the endocytic and 
phagocytic pathways, has been shown to play a crucial role in antigen 
cross-presentation for effective anti-tumor immunity in vivo (46).
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It is also clear that cross-priming is the final event of a meta-
bolic and tightly regulated reprogramming of the DCs, also in 
response to extracellular stimuli.
In DCs, the mTOR network integrates extracellular molecular 
cues, such as nutrient, stress, PAMPs, and DAMPs, and triggers 
transcriptional and metabolic reprogramming of DCs (47). The 
balance between cross-presentation of exogenous antigens and 
lysosome activity in DCs is promptly switched by the transcrip-
tion factor EB (TFEB), regulated by mTOR pathway (48).
It is interesting to note that mTOR, TFEB, and molecules 
involved in intracellular protein trafficking such as Sec22b are 
found in tumor-derived MVs (49–52).
Whether tumor MVs may activate other metabolic processes 
resulting in phagosomal alkalinization, as early response, and 
then cross-processing, as late event, remains to be determined 
and further investigations are required to decipher the complex 
role that tumor MVs play in the cross talk among tumor, immune 
cells, and tissue microenvironment.
At our knowledge, this is the first evidence that tumor MVs have 
been described to reprogram DC antigen-processing machinery 
by ROS-mediated mechanism, inducing early alkalinization 
of the phagosomal compartment and sustaining antigen cross- 
processing.
This mechanism can be relevant for shaping antigen immuno-
genicity in vivo, also for those large tumor glycosylated antigens 
as such as MUC1. These findings may further support the exploi-
tation of tumor-derived MVs for the design of cell-free-based 
immunogens for anti-cancer therapy (53).
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